Skip to content

The Association Analysis of PTPN1 Gene SNP with Type 2 Diabetic Retinopathy and Nephropathy in a Chinese Population and the Development of a Predictive Nomogram

The Association Analysis of PTPN1 Gene SNP with Type 2 Diabetic Retinopathy and Nephropathy in a Chinese Population and the Development of a Predictive Nomogram

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500107654
Enrollment
Unknown
Registered
2025-08-15
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Interventions

T2DM group :none

Sponsors

Ningbo Medical Centre Lihuili Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Han Chinese adults aged 18-80 years who meet the 2019 American Diabetes Association (ADA) diagnostic criteria for T2DM, specifically fasting blood glucose >=7.0 mmol/L, or 2-hour postprandial blood glucose >=11.1 mmol/L, or glycated hemoglobin >=6.5%, or random blood glucose >=11.1 mmol/L accompanied by typical diabetic symptoms. Additionally, they should have a disease duration of >=1 year and complete medical records.

Exclusion criteria

Exclusion criteria: 1. Patients with type 1 diabetes mellitus, gestational diabetes, or secondary diabetes; 2. those with acute diabetic complications such as diabetic ketoacidosis or hyperosmolar hyperglycemic state; 3. those with severe cardiovascular and cerebrovascular diseases, malignant tumors, severe hepatic or renal insufficiency, autoimmune diseases, or hematological disorders; 4. those who have used medications affecting glucose and lipid metabolism, such as glucocorticoids, within the past three months; 5. those with a history of eye trauma, glaucoma, cataract surgery, or other non-diabetic retinal diseases; 6. those with non-diabetic kidney diseases such as chronic nephritis or polycystic kidney disease; 7. and those who refuse to participate in the study or are unable to cooperate with relevant examinations.

Design outcomes

Secondary

MeasureTime frame
eGFR;Blood glucose;24-hour urine protein quantification;Urine albumin-to-creatinine ratio;Complete blood count (CBC);

Primary

MeasureTime frame
Genotyping by polymerase chain reaction-restriction fragment length;

Countries

China

Contacts

Public ContactQian Dong

Ningbo Medical Centre Lihuili Hospital

lhldongqian@nbu.edu.cn+86 574 55836226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026